Study Finds that LG Chem’s Biosimilar LBEC0101 is Comparable to Pfizer & Amgen’s Enbrel (Etanercept) for Treatment of Patients With Rheumatoid Arthritis

On 5 March 2024, a study published in Modern Rheumatology found that LG Chem’s LBEC0101, the biosimilar of etanercept, matches up to the reference product in terms of effectiveness and safety in the real-world treatment of rheumatoid arthritis. This evidence was gathered from the Kyoto University Rheumatoid Arthritis Management Alliance cohort, including patients treated between 2015 and 2021. The study reports that patients who switched from the reference product to LBEC0101 did not experience any significant differences in their treatment outcomes.